Patents by Inventor Keith David Wilner

Keith David Wilner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10695426
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: June 30, 2020
    Assignees: Pfizer Inc., Merck Sharp & Dohme Corp.
    Inventors: Leena Das-Young, Keith David Wilner, Steffan Nicholas Ho
  • Publication number: 20190275049
    Abstract: This invention relates to a method of treating non-small cell lung cancer by administering an EGFR T790M inhibitor in combination with a CDK inhibitor to a patient in need thereof.
    Type: Application
    Filed: November 7, 2017
    Publication date: September 12, 2019
    Applicant: PFIZER INC.
    Inventors: Zelanna Iris GOLDBERG, Yuli WANG, Scott Lawrence WEINRICH, Keith David WILNER
  • Publication number: 20170274074
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.
    Type: Application
    Filed: August 24, 2015
    Publication date: September 28, 2017
    Inventors: Leena Das-Young, Keith David Wilner, Steffan Nicholas Ho